AUPH News and Press, Aurinia Pharmaceuticals Inc From 10/22/20

- Integrated analysis confirms statistically superior efficacy and safety of voclosporin in combination with MMF and steroids over standard-of-care – - Voclosporin pharmacokinetic data supports consistent dose-response, potentially eliminating the need for therapeutic d...

Aurinia’s voclosporin demonstrated exceptional Phase 3 trial results to treat Lupus Nephritis “LN”, a significant unmet medical need with blockbuster potential. Voclosporin’s PDUFA date is in January 2021 and Aurinia is prepared to commercialize the drug on...

Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company aiming to develop and commercialize therapies for Lupus Nephritis ("LN") and Dry Eye Syndrome ("DES"). Aurinia's LN therapeutic Voclosporin has completed Phase 3 and is awaiting NDA results at the PDUFA target ...

Aurinia Pharmaceuticals (AUPH) announces Time Is Nephrons, the first-ever lupus nephritis ((LN)) disease-state awareness campaign for healthcare professionals.The initiative aims to highlight the importance of active screening for early diagnosis to minimize the impact on kidney function...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced Time Is Nephrons, the first-ever lupus nephritis (LN) disease-state awareness campaign for healthcare professionals (HCPs). The initiative aims to highlight the ...

- Voclosporin ophthalmic solution (VOS) results on track to be reported in the fourth quarter of 2020 - - Study builds on positive head-to-head data with approved treatment reported in prior Phase 2a study - - Dry eye syndrome is a chronic autoimmune disorder affecting...

The following slide deck was published by Aurinia Pharmaceuticals Inc. in conjunction with this Read more ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the senior management team will participate in fireside chats during the following upcoming virtual investor conferences: H.C. Wainwright & Co. 22 nd Annual Global I...

The Dry Eye Syndrome is a relatively common disease whose prevalence increases as people age. It is believed that more than 6% of the population over age of 40 and 15% of the population over age of 65 is impacted by DES in US, with symptoms that vary from mild (redness, irritation, etc.) to se...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company’s Compensation Committee granted 105...